

Proteasome inhibitors decrease paclitaxel-induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1

LING HU^{1,2*}, XI PAN^{3*}, JINYUE HU^{1,2,4}, HONG ZENG⁵, XUETING LIU^{1,2},
MANLI JIANG^{1,2} and BINYUAN JIANG^{1,2,4}

¹Medical Research Center, ²Changsha Cancer Institute, Changsha Central Hospital, University of South China, Changsha, Hunan 410004; ³Department of Oncology, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013; ⁴Department of Clinical Laboratory, Changsha Central Hospital, University of South China, Changsha, Hunan 410004; ⁵Reproductive Medicine Center, Foshan Maternal and Child Health Care Hospital, Southern Medical University, Foshan, Guangdong 528000, P.R. China

Received March 25, 2021; Accepted July 2, 2021

DOI: 10.3892/ijmm.2021.5026

Abstract. Southeast Asia is a region with high incidence of nasopharyngeal carcinoma (NPC). Paclitaxel is the mainstay for the treatment of advanced nasopharyngeal cancer. The present study investigated the effect of proteasome inhibitors on the therapeutic effect of paclitaxel and its related mechanism. The present data from Cell Counting Kit-8 and flow cytometry assays demonstrated that appropriate concentrations of proteasome inhibitors (30 nM PS341 or 700 nM MG132) reduced the lethal effect of paclitaxel on the nasopharyngeal cancer cells. While 400 nM paclitaxel effectively inhibited cell division and induced cell death, proteasome inhibitors (PS341 30 nM or MG132 700 nM) could reverse these effects. Additionally, the western blotting results demonstrated accumulation of cell cycle regulation protein CDK1 and cyclin B1 in proteasome inhibitor-treated cells. In addition, proteasome inhibitors combined with paclitaxel led to decreased MCL1 apoptosis regulator, BCL2 family member/Caspase-9/poly (ADP-ribose) polymerase apoptosis signaling triggered by CDK1/cyclin B1. Therefore, dysfunction of CDK1/cyclin B1 could be defining the loss of paclitaxel lethality against cancer cells, a phenomenon affirmed by the CDK1 inhibitor Ro3306. Overall, the present results demonstrated that a combination of paclitaxel with proteasome inhibitors or CDK1 inhibitors is antagonistic to effective clinical management of NPC.

Introduction

Nasopharyngeal carcinoma (NPC) is highly prevalent in Southern China and Southeast Asia (1,2). Advanced NPC is often associated with resistance to conventional radiotherapy and chemotherapy (3,4). A combination chemotherapy regimen with different pharmacological mechanism drugs could be an effective strategy to enhance the therapeutic effect (5,6). In the present study, proteasome inhibitor was combined with paclitaxel and their efficacy was evaluated in the treatment of NPC.

Bortezomib (PS341) is an inhibitor of the 26S proteasome, used in the treatment of multiple myeloma, as well as in clinical trials for solid tumors as a single agent or in combination with other drugs (7-9). Proteasome inhibition causes rapid accumulation of ubiquitinated proteins and perturbation of protein metabolism, leading to initiation of apoptosis by the endoplasmic reticulum to overcome irreversible cellular damage (10,11). The ubiquitin-proteasome system is a non-lysosomal protein degradation pathway, which regulates numerous eukaryotic cell signaling pathways, including the cell cycle (12). In the cell cycle pathway, two families of E3 ubiquitin ligases, anaphase promoting complex or cyclosome (APC/C) and Skp1/CUL1/F-box protein, are responsible for periodic proteolysis of cell cycle regulators, ensuring regulated cell cycle progression (13).

On the other hand, paclitaxel is a member of the taxane class of drugs, used as an anti-microtubule agent in the treatment of cancer, including NPC (14). Binding of paclitaxel to β -tubulin dimers inhibits the hydrolysis of GTP, resulting in microtubule stabilization and loss of dynamics (15). Dysfunction of microtubules causes incorrect spindle-chromosome attachment and prolonged mitotic arrest, resulting in mitotic catastrophe, and initiation of cell death to prevent transmission of erroneous genetic information (16,17).

Mitotic catastrophe refers to cell death associated with inappropriate mitosis or irreversible cell cycle arrest (18). Cells that undergo mitotic catastrophe are morphologically distinguishable, since nuclear envelopes form around individual or

Correspondence to: Dr Binyuan Jiang, Medical Research Center, Changsha Central Hospital, University of South China, 161 Shaoshan South Road, Changsha, Hunan 410004, P.R. China
E-mail: jby2225859@126.com

*Contributed equally

Key words: paclitaxel, proteasome inhibitor, nasopharyngeal carcinoma, CDK1/cyclin B1

groups of chromosomes, resulting in large nonviable cells with multiple micronuclei (19,20). Mitotic catastrophe has been proposed to be a tumor suppression mechanism, while evasion of mitotic catastrophe constitutes one of the mechanisms of cancer development (21). Cells typically undergo prolonged mitotic arrest when treated with antimetabolic drugs, and the cell fate is determined by assessing the slow or sudden degradation of cyclin B1 resulting in mitotic slippage or activation of cell death pathways, respectively (22). The activation of cell death pathways leads to accumulation of death activators or loss of death inhibitors (23). Additionally, mitotic cell death results from intracellular signals breaching the death threshold before achieving the mitotic slippage threshold (24).

The CDK1/cyclin B1 complex is essential for cell cycle progression in eukaryotes. Cyclin B1 is a regulatory subunit, while CDK1 is a catalytic subunit (25). CDK1 phosphorylates a number of mitotic substrates, which are involved in mitotic spindle generation, chromosome condensation, nuclear envelope breakdown and mitotic death (26). Accumulation of the CDK1-cyclin B1 proteins is critical for the activation of CDK1 and entry of mitosis (27). In addition to cyclin B1 binding, CDK1 activation requires the phosphorylation at T161 of its activation segment and the dephosphorylation of Y15 and T14 residues (28). After mitosis, destruction of cyclin B1 provides a mechanism to rapidly inactivate CDK1 and exit mitosis, and CDK1/cyclin B1 catalyzes its own destruction by stimulating the activity of APC/C^{CDC20} (29). When cells undergo inappropriate mitosis or irreversible cell cycle arrest after treatment with antimetabolic drugs, the mitotic cells also require the sudden degradation of CDK1/cyclin B1 and the breaching of the death threshold (30,31).

In the present study examined the combination chemotherapy regimen, and revealed that proteasome inhibitor PS341 markedly decreased the number of rounded cells in paclitaxel-treated NPC. Accordingly, the present study aimed to investigate the effect of proteasome inhibitor in attenuating the lethality of paclitaxel against NPC cells and to explore its related molecular mechanism.

Materials and methods

Cell culture and drugs. The 5-8F and 6-10B NPC cell lines (Cancer Center of Sun Yat-sen University, Guangzhou, China) used in the present study were cultured in DMEM (Biological Industries) with 10% FBS (Biological Industries), penicillin (100 U/ml; Biological Industries) and streptomycin (100 µg/ml; Biological Industries) in a humidified incubator with 5% CO₂ at 37°C. Paclitaxel, PS341, MG132, Ro3306 and cycloheximide were purchased from MedChemExpress. Flutax1 was purchased from R&D Systems, Inc. The cells were cultured with paclitaxel (400 nM), flutax1 (3 µM), PS341 (30 nM), MG132 (700 nM), Ro3306 (5 µM) or cycloheximide (1 µg/ml) in a humidified incubator with 5% CO₂ at 37°C for 24 or 48 h during the test. In addition, the sets and procedure of the cycloheximide assay (Fig. S1) were as follows: Two sets were cycloheximide-treated cells and non-cycloheximide-treated cells, and each set contained four groups: NC (0.5%, v/v, DMSO), PTX (400 nM), PS341 (30 nM) and PTX (400 nM)-PS341 (30 nM). Cycloheximide-treated cells were cultured as groups for 16 h, then cycloheximide (1 µg/ml) was

added for a further 8-h treatment, and cells were harvested at 24 h. While non-cycloheximide-treated cells were cultured as groups and harvested at 24 h. The used drug concentrations were tested against 5-8F and 6-10B cells in the present study based on the following principles: Paclitaxel and flutax1 were used at a lethal concentration, and PS341, MG132, Ro3306 and cycloheximide were used at low toxicity concentrations or nontoxic concentrations, ensuring cell proliferation inhibition and death were mainly caused by taxol analogues. After cell attachment, taxol-analogues and PS341, MG132 or Ro3306 were added simultaneously.

Cell Counting Kit-8 (CCK-8) assay. To examine the effect on cell proliferation, 15,000 cells per well were seeded in a 96-well plate in DMEM with 10% FBS (n=3). After cell adhesion, the medium was replaced with a fresh complete medium containing drugs at the corresponding concentrations as follow: Negative control (NC; 0.5%, v/v, DMSO), PTX (400 nM), PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM), PTX (400 nM)-MG132 (700 nM), PTX (400 nM)-PS341 (0, 5, 10, 25, 50 or 100 nM), PTX (400 nM)-MG132 (0, 50, 100, 200, 400 or 700 nM), Ro3306 (5 µM) or PTX (400 nM)-Ro3306 (5 µM). A total of 10 µl CCK-8 reagent (Shanghai Yeasen Biotechnology Co., Ltd.) was added to each well every 24 h for 2 days. The cells were incubated for 1 h and then absorbance at 450 nm was measured using a microplate reader (ELx800; BioTek Instruments, Inc.).

Western blotting. To examine the related protein expression changes, 5x10⁵ cells per well were seeded in a 12-well plate with DMEM with 10% FBS. After cell culture in a humidified incubator with 5% CO₂ at 37°C for cell adhesion, the medium was replaced with a fresh complete medium containing drugs at the corresponding concentrations as follows: Negative control (NC; 0.5%, v/v, DMSO), PTX (400 nM), PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM), PTX (400 nM)-MG132 (700 nM), Ro3306 (5 µM) or PTX (400 nM)-Ro3306 (5 µM). After 24 or 48 h, cells were harvested and lysed in Cell lysis buffer for Western and IP (Beyotime Institute of Biotechnology). The BCA Protein Assay kit (Beyotime Institute of Biotechnology) was selected for protein concentration determination. A total of 20 µg total proteins were loaded per lane and resolved by 10% SDS-PAGE, and then transferred onto a 0.45-µm PVDF membrane (MilliporeSigma), except p21 Waf1/Cip1 which was transferred onto a 0.22-µm PVDF membrane (MilliporeSigma). The membrane was blocked in PBS with 0.05% Tween-20 (PBST) with 5% w/v nonfat dry milk at room temperature for 1 h, then washed three times in PBST for 2 min each at room temperature, followed by incubation with primary antibody in PBST with gentle agitation at 4°C overnight. The membrane was washed three times for 10 min each in PBST and then incubated with an HRP-conjugated secondary antibody at room temperature for 60 min in PBST. After three washes for 5 min each in PBST, the signal was visualized using an ECL detection reagent (Thermo Fisher Scientific, Inc.) and imaged. Ubiquitin antibody (cat. no. 3933; dilution, 1:1,000), CDK1 antibody (cat. no. 77055; dilution, 1:1,000), phosphorylated (p)-CDK1(Thr14) antibody (cat. no. 2543; dilution, 1:1,000), p-CDK1(Thr161) antibody (cat. no. 9114; dilution, 1:1,000), p21 Waf1/Cip1 antibody (cat. no. 2947; dilution,

1:1,000), MCL1 apoptosis regulator, BCL2 family member (MCL1) antibody (cat. no. 94296; dilution, 1:1,000), caspase-9 antibody (for detection of procaspase-9 and cleaved caspase-9; cat. no. 9502; dilution, 1:1,000), poly (ADP-ribose) polymerase (PARP) antibody (for detection of full-length PARP and cleaved PARP; cat. no. 9532; dilution, 1:1,000) were purchased from Cell Signaling Technology, Inc. Cyclin D1 (cat. no. AF1183; dilution, 1:1,000), cyclin E1 (cat. no. AF2491; dilution, 1:1,000), cyclin A2 (cat. no. AF2524; dilution, 1:1,000), cyclin B1 (cat. no. AF6627; dilution, 1:1,000), aurora A (cat. no. AF1708; dilution, 1:1,000), aurora B (cat. no. AF1930; dilution, 1:1,000) and GAPDH (cat. no. AF0006; dilution, 1:2,000) primary antibodies were purchased from Beyotime Institute of Biotechnology. GAPDH was used as a control. The secondary antibodies, including anti-rabbit IgG, HRP-linked antibody (cat. no. 7074; dilution, 1:2,000) and anti-mouse IgG, HRP-linked antibody (cat. no. 7076; dilution, 1:2,000), were purchased from Cell Signaling Technology, Inc. Grayscale semi-quantifications of bands was performed using ImageJ software (version 1.42q; National Institutes of Health). GAPDH was used as a loading control for total protein, the grayscale values of each protein band were normalized to GAPDH within groups, and relative protein levels were normalized to the control group.

Cell microscopic observation. To examine the paclitaxel-induced cell morphology changes, 3×10^5 cells per well were seeded in a 24-well plate with DMEM with 10% FBS. After cell culture in a humidified incubator with 5% CO₂ at 37°C for cell adhesion, the medium was replaced with a fresh complete medium containing drugs at the corresponding concentrations as follows: NC (0.5% v/v DMSO), PTX (400 nM), PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM), PTX (400 nM)-MG132 (700 nM). After culture in a humidified incubator with 5% CO₂ at 37°C for 24 h, the cells were observed under a Leica DM IL LED inverted light microscope (Leica Microsystems, Inc.) and images were captured. The ratio of rounded cells to total cells in five random fields of vision (magnification, x200) was counted. To examine the paclitaxel-induced nuclear condensation in NPC cells, Hoechst 33342 Staining Solution for Live Cells 100X (cat. no. C1028; Beyotime Institute of Biotechnology) was used to stain the nucleus. After removing the medium and rinsing with PBS, nuclei were stained with 200 μ l diluted Hoechst 33342 (dilution, 1:100) per well for 10 min at 37°C, rinsed three times with PBS and observed under a fluorescence microscope (Leica Microsystems, Inc.). Merging of the images was performed using ImageJ software (version 1.42q; National Institutes of Health). To examine the taxol-induced microtubule changes, fluorescently labeled taxol flutax1 (R&D Systems, Inc.) was used for tracing taxol in NPC cells, while the transformation of microtubules in flutax1-treated NPC cells was observed using Tubulin-Tracker Red (cat. no. C1050; Beyotime Institute of Biotechnology). After culture with flutax1 (3 μ M), flutax1 (3 μ M)-PS341 (30 nM) and flutax1 (3 μ M)-MG132 (700 nM) in a humidified incubator with 5% CO₂ at 37°C for 24 h, cells were rinsed with PBS two times and fixed with 3.7% paraformaldehyde (Sigma-Aldrich; Merck KGaA) in PBS for 20 min at room temperature. Subsequently, cells were washed three times with PBS containing 0.1% Triton X-100 for 5 min each time at room temperature. Tubulin-Tracker Red

was diluted with PBS containing 3% BSA (Beyotime Institute of Biotechnology) and 0.1% Triton X-100 (Beyotime Institute of Biotechnology), and 200 μ l Tubulin-Tracker Red (dilution, 1:100) was added to each well for 60 min at room temperature, followed by counterstaining with 200 μ l diluted Hoechst 33342 (dilution, 1:100) per well for 10 min at 37°C. After three washes with PBS for 5 min each at room temperature, related results were visualized with a fluorescence microscope (Lionheart; BioTek Instruments, Inc.).

Cell cycle detection. To investigate the cell cycle distribution, 2.5×10^6 cells per well were seeded in a 6-well plate with DMEM with 10% FBS (n=3). After cell adhesion, the medium was replaced with fresh complete medium containing drugs at the corresponding concentrations as follows: NC (0.5% v/v DMSO), PTX (400 nM), PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM), PTX (400 nM)-MG132 (700 nM), Ro3306 (5 μ M) and PTX (400 nM)-Ro3306 (5 μ M). After culture in a humidified incubator with 5% CO₂ at 37°C for 24 h, the cells were harvested and fixed in 75% alcohol at 4°C. After 24 h, 75% alcohol was removed by centrifugation at 500 x g at 4°C for 5 min, followed by two washes with cold PBS. Cells were stained using propidium iodide (PI final concentration, 50 μ g/ml; Beyotime Institute of Biotechnology) and RNase treatment (RNase final concentration, 100 μ g/ml; Beyotime Institute of Biotechnology), and incubated for 20 min at 37°C in the dark. The cell cycle distribution was determined by evaluating DNA content using a BD Accuri C6 Flow Cytometer (BD Biosciences), and the data were analyzed using the BD Accuri C6 Software (version 1.0.264.21; BD Biosciences). The NC group was set as the control when comparing SubG₁ phase change, PTX (400 nM) group was set as the control when comparing restored G₁ phase and decreased G₂/M phase.

Cell apoptosis detection. The cell apoptosis assay was performed using the Annexin V-FITC/PI Apoptosis Detection kit (Shanghai Yeasen Biotechnology Co., Ltd.) according to the manufacturer's protocol. Briefly, 1.5×10^6 cells per well were seeded in a 6-well plate with DMEM with 10% FBS (n=3). After cell adhesion, the medium was replaced with fresh complete medium containing drugs at the corresponding concentrations as follows: NC (0.5% v/v DMSO), PTX (400 nM), PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM), PTX (400 nM)-MG132 (700 nM), Ro3306 (5 μ M) and PTX (400 nM)-Ro3306 (5 μ M). After culture in a humidified incubator with 5% CO₂ at 37°C for 48 h, the cells were harvested by centrifugation at 500 x g at 4°C for 5 min and washed twice with cold PBS, then resuspended in 1X binding buffer at a concentration of 5×10^5 cells/ml. Cells (100 μ l) were resuspended with 5 μ l Annexin V-FITC and 10 μ l PI. After incubation for 15 min at room temperature in the dark, 400 μ l 1X Binding Buffer was added to each tube. The proportion of apoptotic cells was measured using a BD Accuri C6 Flow Cytometer (BD Biosciences) within 1 h, and data were analyzed using the BD Accuri C6 Software (version 1.0.264.21; BD Biosciences). Annexin V-FITC and PI double-positive cells were considered to be late apoptotic cells, while Annexin V-FITC positive and PI-negative cells were considered to be early apoptotic cells. The fold changes in the percentage of apoptotic cells were calculated, and each group

was normalized to the NC group. The NC group was set as the control when comparing fold change of paclitaxel-induced apoptosis, and the PTX (400 nM) group was set as the control when comparing fold change of proteasome inhibitors or Ro3306 decreased paclitaxel-induced apoptosis. All fold change data were normalized to the NC group.

Statistical analysis. All experiments were performed at least in triplicate and data are presented as the mean \pm SD. Data were analyzed using one-way ANOVA or two-way ANOVA with multiple comparison as Tukey's post hoc test or Dunnett's post hoc test as appropriate. Figures were generated and statistical analysis was performed using GraphPad Prism 8.3.0 (GraphPad Software, Inc.). $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Proteasome inhibitors reduce the paclitaxel-specific inhibition of NPC cell proliferation. A CCK-8 assay was performed to determine the inhibition of NPC cell proliferation by proteasome blockers. The present results demonstrated that 5-8F cells and 6-10B cells were still growing after culture with proteasome inhibitor PS341 (30 nM) or MG132 (700 nM) after 48 h. Additionally, both inhibitors reduced the inhibitory effect of paclitaxel on NPC cell proliferation after 48 h, while paclitaxel (400 nM) was toxic to 5-8F and 6-10B cells based on the decreased absorbance values at 48 h (Fig. 1A and B). Accumulation of ubiquitinated-proteins indicated compromised proteasome functions following treatment with PS341 (30 nM) and MG132 (700 nM) after 24 h (Fig. 1C). In addition, the linear plot of CCK-8 results revealed increasing absorbance values at 450 nm with the gradual increase in concentrations of proteasome inhibitors compared with the negative control group (PTX 400 nM). PS341 (10-100 nM) and MG132 (50-700 nM) attenuated the inhibitory effect of paclitaxel (400 nM) on cell proliferation after 48 h (Fig. 1D). Therefore, proteasome inhibition was associated with reduced lethality of paclitaxel.

Proteasome inhibitors reduce paclitaxel-specific morphological changes in NPC cells. Paclitaxel-induced mitotic catastrophe often leads to changes in cell morphology and chromatin condensation after 24 h (31). The present findings demonstrated that proteasome inhibitors markedly reduced the paclitaxel-specific morphological changes and multiple micronuclei of NPC cells after 24 h (Fig. 2A-D). Representative images (magnification, x40; top rows in Fig. 2A and B) revealed that most of the paclitaxel-treated cells were rounded; however, rounded cells decreased when the cells were treated with paclitaxel and proteasome inhibitors (PS341 or MG132) synchronously. The ratio of rounded cells and total cells in five random fields of vision (magnification, x200; bottom row in Fig. 2A and B) was determined. The results of statistical analyses indicated that proteasome inhibitors significantly decreased paclitaxel-induced rounded cells. These data demonstrated that the proteasome inhibitors aided the NPC cells in evading mitotic catastrophe after 24 h, speculated that more NPC cells survived with spindle-chromosome attachment errors represented higher chromosome mutation risk.

Proteasome inhibitors decrease the paclitaxel-induced cell cycle arrest in NPC cells. To determine the cell cycle profile in the drug-treated NPC cells after 24 h, the DNA content was evaluated using flow cytometry. Compared with NC groups, addition of paclitaxel increased the percentage of Sub G₁ phase cells in the PTX (400 nM), PTX (400 nM)-PS341 (30 nM) and PTX (400 nM)-MG132 (700 nM) groups. Paclitaxel blocked almost all NPC cells at the G₂/M phase; however, when the cells were treated with paclitaxel and proteasome inhibitors (PS341 or MG132) synchronously, the G₁ phase was significantly restored and G₂/M phase was significantly decreased compared with the paclitaxel-treated group (Fig. 3A). These results combined with the CCK-8 assay data (Fig. 1A and B) suggested that proteasome inhibitors could help NPC cells in escaping paclitaxel-induced mitotic arrest and proliferation inhibition.

Proteasome inhibitors reduce paclitaxel-induced cell death in NPC cells. Apoptosis is the main outcome of mitotic catastrophe-induced cell death (32). An Annexin V-FITC/PI assay was performed to determine the effect of paclitaxel coupled with proteasome inhibitors on cell apoptosis after 48 h. Compared with the NC groups, addition of paclitaxel in the PTX (400 nM), PTX (400 nM)-PS341 (30 nM) and PTX (400 nM)-MG132 (700 nM) groups increased the percentage of apoptotic cells. When the cells were treated with paclitaxel and proteasome inhibitors (PS341 or MG132) synchronously, the percentage of apoptotic cells was significantly decreased compared with that in the paclitaxel-treated group. The data demonstrated a marked reduction of paclitaxel-induced apoptosis in NPC cells by the proteasome inhibitors (Fig. 3B).

Proteasome inhibitors lead to an enlarged microtubule cytoskeleton system and freed nuclear condensation of NPC cells treated with flutax1. Furthermore, the present study used fluorescently labeled taxol flutax1 (green) to treat NPC cells, tubulin-tracker (red) to label microtubules, and hoechst 33342 (blue) to stain DNA to extract more data from microtubule stabilized cells. In the Flutax1 (3 μ M) group, most of the flutax1-treated NPC cells (green) presented multiple micronuclei (blue) after 24 h, and pyknotic microtubules (red) wrapped with these condensed genetic materials (Fig. 4A; first and fourth row). Condensed microtubules and chromatin indicated that the mitotic spindle failed in separating chromosomes to their respective poles, and most NPC cells were stuck in the mitosis phase for taxol-treatment (33). Notably, a combination of flutax1 and proteasome inhibitors (PS341 or MG132) led to an enlarged microtubule cytoskeleton system and fewer multiple micronuclei in NPC cells, and also fewer NPC cells were stuck in the mitosis phase (Fig. 4A).

Proteasome inhibitors alter the expression pattern of the CDK1/cyclin B1 protein in NPC cells. There are four main types of cyclin in human cells, cyclin D1 (protein exists throughout the cell cycle, triggers cell from G₀ to G₁ and G₁ to S phase), cyclin E1 (protein mainly exists during G₁/S phase, preparing for DNA replication in S phase), cyclin A2 (protein mainly exists during G₂/M transition, for the activation of DNA replication in S phase) and cyclin B1 (protein mainly exists during G₂/M phase, for the assembly of mitotic spindle and mitosis promotion) (34,35). In the present study,




Figure 1. Proteasome inhibitors reduce the paclitaxel-specific inhibition of nasopharyngeal carcinoma cell proliferation. Cell Counting Kit-8 assays demonstrated that PS341 or MG132 significantly decreased the paclitaxel-induced inhibition of proliferation of (A) 5-8F and (B) 6-10B cells. The data are presented as the mean \pm SD (n=3) and were analyzed using two-way ANOVA followed by Tukey's post hoc test. *P<0.05 vs. PTX (400 nM) group at 48 h. (C) Western blot analysis revealed that PS341 (30 nM) or MG132 (700 nM) inhibited the functions of the proteasome in ubiquitinated protein degradation. (D) A gradual increase in the concentration of proteasome inhibitors PS341 (10-100 nM) and MG132 (50-700 nM) attenuated the inhibitory effect of paclitaxel (400 nM) on cell proliferation. The data are presented as the mean \pm SD (n=3) and were analyzed using two-way ANOVA followed by Dunnett's post hoc test. *P<0.05 vs. PTX (400 nM)-PS341/MG132 (0 nM) group. NC, negative control; OD, optical density; PS341, bortezomib; PTX, paclitaxel.

paclitaxel-treated NPC cells were blocked at M phase after 24 h. Compared with the NC group of 5-8F and 6-10B cells in Fig. 4B, the expression profile of cyclin-related proteins in the PTX (400 nM) group exhibited mitotic phase-specific features, such as low expression levels of cyclin E1 (during G₁/S phase) and cyclin A2 (during G₂/M transition), and high expression levels of aurora A and cyclin B1. Additionally, there was a reduction of CDK1 expression in the PTX (400 nM) group. On the other hand, the combination of paclitaxel and proteasome inhibitors restored cyclin E1 and cyclin A2 expression in the PTX (400 nM)-PS341 (30 nM) and PTX (400 nM)-MG132 (700 nM) groups. The inhibition of proteasomes led to high expression levels of both CDK1 and cyclin B1 in proteasome

inhibitor-treated groups [PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM) and PTX (400 nM)-MG132 (700 nM)] compared with the NC group (Fig. 4B). The contrast of the CDK1/cyclin B1 expression pattern between the PTX (400 nM) group (high cyclin B1 and low CDK1 expression compared with NC group) and proteasome inhibitor-treated groups (high cyclin B1 and high CDK1 expression compared with NC group) suggested that proteasome inhibitor-induced alterations in the CDK1/cyclin B1 expression pattern could be essential for escaping paclitaxel-induced mitotic arrest.

Proteasome inhibitors reduce paclitaxel-initiated cell death via CDK1/cyclin B1 signaling. Considering the onset time of




Figure 2. Proteasome inhibitors reduce paclitaxel-induced morphological changes and nuclear condensation in NPC cells. Proteasome inhibitors (PS341 and MG132) significantly reduced the paclitaxel-induced morphological changes of (A) 5-8F and (B) 6-10B cells. The data are presented as the mean \pm SD (n=5) and were analyzed using one-way ANOVA followed by Tukey's post hoc test. *P<0.05. Magnification, $\times 40$; scale bar, $500 \mu\text{m}$ (top row). Magnification, $\times 200$; scale bar, $100 \mu\text{m}$ (bottom row). Proteasome inhibitors reduced nuclear condensation in rounded (C) 5-8F and (D) 6-10B cells. Magnification, $\times 200$; scale bar, $100 \mu\text{m}$. NC, negative control; NPC, nasopharyngeal carcinoma; PS341, bortezomib; PTX, paclitaxel.

paclitaxel-initiated cell death and the key role of CDK1/cyclin B1 in mitosis regulation, the present study examined the expression profile of CDK1/cyclin B1 and its related proteins at 24 and 48 h. In the paclitaxel-treated NPC cells, CDK1 was activated (compared with NC groups, T161 phosphorylation was increased and T14 phosphorylation was decreased) at

24 h, while cyclin B1 proteolysis and the caspase-9/PARP apoptosis cascade were activated at 48 h. In the present study, p-CDK1 T161 separated into two bands: Band 1 reflected T161 phosphorylation combination with inhibitory phosphorylation of either T14 or Y15, whereas band 2 reflected the active single T161 phosphorylated form of CDK1. In the




Figure 3. Proteasome inhibitors decrease paclitaxel-induced cell cycle arrest and apoptosis of nasopharyngeal carcinoma cells. (A) Proteasome inhibitors (PS341 and MG132) significantly reduced the paclitaxel-induced G₂/M phase arrest at 24 h. The data are presented as the mean ± SD (n=3) and were analyzed using two-way ANOVA followed by Tukey's post hoc test. *P<0.05. (B) Proteasome inhibitors significantly reduced paclitaxel-induced apoptosis. The data are presented as the mean ± SD (n=3) and were analyzed using one-way ANOVA followed by Tukey's post hoc test. *P<0.05. NC, negative control; PS341, bortezomib; PTX, paclitaxel.

proteasome inhibitor-treated NPC cells, PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM) and PTX (400 nM)-MG132 (700 nM) groups sustained the high expression levels of CDK1/cyclin B1 proteins, and multi-band T161 phosphorylation status of CDK1. Multisite phosphorylation of CDK1 prevents its premature activation and demonstrates that the cells are distributed in a different phase of the cell cycle (28). Additionally, compared with paclitaxel-treated cells in the PTX (400 nM) group, there was persistent high CDK1/cyclin B1 protein expression with MCL1 accumulation, less cleavage of caspase-9 and PARP in the PS341 (30 nM), PTX (400 nM)-PS341 (30 nM), MG132 (700 nM) and PTX (400 nM)-MG132 (700 nM) groups (Fig. 4C). Following culture with cycloheximide for 8 h, PS341 was also associated with accumulation of cyclin B1 and MCL1 proteins in 5-8F and 6-10B cells at 24 h (Fig. S1).

Inhibition of CDK1 by Ro3306 decreases the paclitaxel-induced mitotic catastrophe. Ro3306, a potent and selective inhibitor of CDK1 (36), also decreased paclitaxel-induced mitotic catastrophe and cell death in NPC cells in the present study. When the cells were treated with paclitaxel and Ro3306, compared with the PTX (400 nM) group, the optical density results of

the CCK-8 assay at 48 h were significantly increased in the PTX (400 nM)-Ro3306 (5 μM) group (Fig. 5A), there was a decreased paclitaxel-specific inhibition of cell proliferation. In apoptotic cell detection, compared with the NC group, the addition of paclitaxel in the PTX (400 nM) and PTX (400 nM)-Ro3306 (5 μM) groups increased the percentage of apoptotic cells (Figs. 5B and S2). When the cells were treated with paclitaxel and Ro3306, compared with PTX (400 nM) group, the paclitaxel-induced apoptosis in the PTX (400 nM)-Ro3306 (5 μM) group was decreased (Figs. 5B and S2). In addition, western blotting results indicated that Ro3306 decreased the paclitaxel-induced apoptosis signaling via the MCL1/caspase-9/PARP signaling pathway (Fig. 5C). Therefore, loss of paclitaxel lethality may be due to the inhibition of CDK1.

Discussion

A combination of drugs with different mechanisms presents an alternative and effective strategy in enhancing cancer therapeutic effects. For instance, in paclitaxel-resistant ovarian cancer, PS341 restores paclitaxel-induced cell death by alteration of microtubule dynamics and hedgehog signaling (37).




Figure 4. Proteasome inhibitors perturb CDK1/cyclin B1 functions in regulating the NPC cell cycle. (A) Proteasome inhibitor-treated NPC cells were freed from nuclear condensation induced by flutax1 and had an enlarged microtubule cytoskeleton system. Magnification, x200; scale bar, 100 μm. (B) NPC cells treated with the proteasome inhibitors presented a different cell cycle proteins profile compared with the paclitaxel-treated cells at 24 h, particularly in terms of CDK1 and cyclin B1. (C) Proteasome inhibitors altered the expression profile of CDK1/cyclin B1 and decreased paclitaxel-induced apoptosis through MCL1 accumulation and caspase-9 stabilization at 24 and 48 h. Representative western blotting results from three independent experiments. Grayscale semi-quantification of bands was performed using ImageJ software. Control group was normalized to 1. Data are presented as fold change in protein expression relative to the control group. No protein detected was marked as '-'. MCL1, MCL1 apoptosis regulator, BCL2 family member; NC, negative control; NPC, nasopharyngeal carcinoma; p-, phosphorylated; PARP, poly (ADP-ribose) polymerase; PS341, bortezomib; PTX, paclitaxel.

Furthermore, in H-ras-dependent paclitaxel-resistant epithelial solid tumors, PS341 blocks Bcl-2-like protein 11 (BIM) degradation and restores BIM-dependent apoptosis associated with paclitaxel treatment (38). Therefore, the combination of paclitaxel with PS341 appears to be a promising tumor chemotherapeutic alternative in overcoming paclitaxel-resistance. While a previous clinical trial associated the use of PS341 with striking toxicity and limited clinical benefit in solid tumors (39-42), the drug is recommended in refractory advanced solid tumors and unresectable stage III non-small-cell lung cancer (43-46). Therefore, more trials are required to further dissect the effects of the use of PS341 with paclitaxel.

In antimitotic drug-induced prolonged mitotic arrest of cells, CDK1/cyclin B1 can be regarded as a hinge between survival and death (47). Stabilization and persistent activation of CDK1/cyclin B1 maintains cells in the mitosis phase (48). Rapid degradation of cyclin B1 and inactivation of CDK1 promote cell death pathways with accumulation of death activators and loss of death inhibitors (49). For example, caspase-9 and MCL1 are typical apoptosis and anti-apoptosis proteins, respectively, regulated by CDK1 (50,51). CDK1 phosphorylates caspase-9 at an inhibitory site to prevent caspase-9 cleavage, while phosphorylation of MCL1 at the T92 site triggers its degradation (50,51). During paclitaxel-induced mitotic arrest,




Figure 5. Ro3306 decreases paclitaxel-induced mitotic catastrophe in nasopharyngeal carcinoma cells. (A) Cell Counting Kit-8 assays illustrated that Ro3306 decreased paclitaxel-induced inhibition of proliferation of 5-8F and 6-10B cells. The data are presented as the mean \pm SD (n=3) and were analyzed using two-way ANOVA followed by Tukey's post hoc test. *P<0.05 vs. PTX (400 nM) group. (B) Ro3306 significantly reduced paclitaxel-induced apoptosis. The data are presented as the mean \pm SD (n=3) and were analyzed using one-way ANOVA followed by Tukey's post hoc test. *P<0.05. (C) Ro3306 decreased paclitaxel-induced MCL1 proteolysis and caspase-9/PARP cleavage. Representative western blotting results from three independent experiments. Grayscale semi-quantification of bands was performed using ImageJ software. Control group was normalized to 1. Data are presented as fold change in protein expression relative to the control group. No protein detected was marked as '-'. MCL1, MCL1 apoptosis regulator, BCL2 family member; NC, negative control; OD, optical density; PARP, poly (ADP-ribose) polymerase; PTX, paclitaxel.

rapid degradation of cyclin B1 activates death signals, such as MCL1 hydrolysis and the cleavage of caspase-9 (52).

The present results demonstrated that nontoxic concentrations of proteasome inhibitors and CDK1 inhibitor RO3306

decreased the paclitaxel-induced mitotic death in NPC cells. It was hypothesized that the perturbed CDK1/cyclin B1 balance in mitosis could be defining the reduced mitotic death. Additionally, when restraining CDK1/cyclin B1 destruction via blockage of the ubiquitin-proteasome pathway, the side-effect of proteasome inhibition could further lead to accumulation of p21^{Waf1/Cip1} and MCL1 (53,54). P21^{Waf1/Cip1} can interact with CDK1 and inhibits its function (55). Accumulation of MCL1 was associated with higher anti-apoptotic signaling (52), and this side-effect of proteasome inhibitors may have enhanced the suppression in CDK1/cyclin B1-triggered cell death. Therefore, it was hypothesized that the mechanism of proteasome inhibitors in disturbing CDK1 function is more complex and stronger than that of RO3306. Whereas the CDK1/cyclin B1 catalytic activity defines the mitosis-promoting factor, data on its role in mitosis remains insufficient. Additionally, data on when and how rapidly CDK1/cyclin B1 is activated in mammalian cells, as well as reorganization of the cell as it enters and exits mitosis is limited (56,57).

The present study demonstrated that NPC cells treated with nontoxic doses of proteasome inhibitors block proliferation without CDK1/cyclin B1 extinction. Combined with previous data (58,59), it was suggested that CDK1/cyclin B1 could be more closely associated with the regulation of apoptosis compared with cell reproduction. CDK1/cyclin B1 functions as a rate-limiting regulator but is not essential for mitotic entry and progression in mammalian somatic cells (60). It was hypothesized that the side-effect of proteasome inhibitors could be vital in cell cycle-related research, especially in cell cycle regulation and anti-mitotic drug resistance.

In conclusion, the present study demonstrated that the abnormal accumulation of CDK1/cyclin B1 protein could be mediating the suppressed effects of paclitaxel when used in combination with proteasome inhibitors. Therefore, increased caution is required when using a combination of paclitaxel with proteasome or CDK1 inhibitors in the treatment of NPC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81802952), the Natural Science Foundation of Hunan Province (grant no. 2020JJ5608), the Scientific Research Funds of Health Commission of Hunan Province (grant no. B2019141), and the Science and Technology Program Foundation of Changsha (grant no. kq1901017).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LH, XP, HZ and BJ performed the experiments. XL and MJ analyzed the data. JH conducted literature search and data interpretation. BJ drafted the initial manuscript. BJ and JH

confirm the authenticity of all the raw data. BJ designed and supervised the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J: Nasopharyngeal carcinoma. *Lancet* 394: 64-80, 2019.
- Ji MF, Sheng W, Cheng WM, Ng MH, Wu BH, Yu X, Wei KR, Li FG, Lian SF, Wang PP, *et al*: Incidence and mortality of nasopharyngeal carcinoma: Interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. *Ann Oncol* 30: 1630-1637, 2019.
- Vasan N, Baselga J and Hyman DM: A view on drug resistance in cancer. *Nature* 575: 299-309, 2019.
- Kaidar-Person O, Gil Z and Billan S: Precision medicine in head and neck cancer. *Drug Resist Updat* 40: 13-16, 2018.
- Madani Tonekaboni SA, Soltan Ghorraie L, Manem VSK and Haibe-Kains B: Predictive approaches for drug combination discovery in cancer. *Brief Bioinform* 19: 263-276, 2018.
- Wong AS, Soo RA, Lu JJ, Loh KS, Tan KS, Hsieh WS, Shakespeare TP, Chua ET, Lim HL and Goh BC: Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma. *Ann Oncol* 17: 1152-1157, 2006.
- Scott K, Hayden PJ, Will A, Wheatley K and Coyne I: Bortezomib for the treatment of multiple myeloma. *Cochrane Database Syst Rev* 4: CD010816, 2016.
- Davies AM, Lara PN Jr, Mack PC and Gandara DR: Incorporating bortezomib into the treatment of lung cancer. *Clin Cancer Res* 13: s4647-4651, 2007.
- Huang IT, Dhungel B, Shrestha R, Bridle KR, Crawford DHG, Jayachandran A and Steel JC: Spotlight on Bortezomib: Potential in the treatment of hepatocellular carcinoma. *Expert Opin Investig Drugs* 28: 7-18, 2019.
- Ri M: Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. *Int J Hematol* 104: 273-280, 2016.
- Manasanch EE and Orłowski RZ: Proteasome inhibitors in cancer therapy. *Nat Rev Clin Oncol* 14: 417-433, 2017.
- Hochstrasser M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. *Curr Opin Cell Biol* 7: 215-223, 1995.
- Skaar JR and Pagano M: Control of cell growth by the SCF and APC/C ubiquitin ligases. *Curr Opin Cell Biol* 21: 816-824, 2009.
- Joerger M: Treatment regimens of classical and newer taxanes. *Cancer Chemother Pharmacol* 77: 221-233, 2016.
- Alushin GM, Lander GC, Kellogg EH, Zhang R, Baker D and Nogales E: High-resolution microtubule structures reveal the structural transitions in alpha-tubulin upon GTP hydrolysis. *Cell* 157: 1117-1129, 2014.
- Weaver BA: How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell* 25: 2677-2681, 2014.
- Shi X and Sun X: Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy. *Cancer Chemother Pharmacol* 80: 909-917, 2017.
- Vitale I, Galluzzi L, Castedo M and Kroemer G: Mitotic catastrophe: A mechanism for avoiding genomic instability. *Nat Rev Mol Cell Biol* 12: 385-392, 2011.
- Roninson IB, Broude EV and Chang BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. *Drug Resist Updat* 4: 303-313, 2001.

20. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: A molecular definition. *Oncogene* 23: 2825-2837, 2004.
21. Denisenko TV, Sorokina IV, Gogvadze V and Zhivotovsky B: Mitotic catastrophe and cancer drug resistance: A link that must to be broken. *Drug Resist Updat* 24: 1-12, 2016.
22. Shi J and Mitchison TJ: Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. *Endocr Relat Cancer* 24: T83-T96, 2017.
23. Brito DA and Rieder CL: Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. *Curr Biol* 16: 1194-1200, 2006.
24. Mc Gee MM: Targeting the mitotic catastrophe signaling pathway in cancer. *Mediators Inflamm* 2015: 146282, 2015.
25. Fung TK and Poon RY: A roller coaster ride with the mitotic cyclins. *Semin Cell Dev Biol* 16: 335-342, 2005.
26. Kalous J, Jansova D and Susor A: Role of cyclin-dependent kinase 1 in translational regulation in the M-Phase. *Cells* 9: 1568, 2020.
27. Yang J, Bardes ES, Moore JD, Brennan J, Powers MA and Kornbluth S: Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. *Genes Dev* 12: 2131-2143, 1998.
28. Coulonval K, Kookan H and Roger PP: Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1 from premature activation. *Mol Biol Cell* 22: 3971-3985, 2011.
29. Lindqvist A, Rodriguez-Bravo V and Medema RH: The decision to enter mitosis: Feedback and redundancy in the mitotic entry network. *J Cell Biol* 185: 193-202, 2009.
30. Sinha D, Duijff PHG and Khanna KK: Mitotic slippage: An old tale with a new twist. *Cell cycle* 18: 7-15, 2019.
31. Mascaraque M, Delgado-Wicke P, Damian A, Lucena SR, Carrasco E and Juarranz A: Mitotic catastrophe induced in HeLa tumor cells by photodynamic therapy with methyl-aminolevulinic acid. *Int J Mol Sci* 20: 1229, 2019.
32. Vakifahmetoglu H, Olsson M and Zhivotovsky B: Death through a tragedy: Mitotic catastrophe. *Cell Death Differ* 15: 1153-1162, 2008.
33. Orth JD, Kohler RH, Fojter F, Sorger PK, Weissleder R and Mitchison TJ: Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. *Cancer Res* 71: 4608-4616, 2011.
34. Jackman M, Kubota Y, den Elzen N, Hagting A and Pines J: Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. *Mol Biol Cell* 13: 1030-1045, 2002.
35. Harashima H, Dissmeyer N and Schnittger A: Cell cycle control across the eukaryotic kingdom. *Trends Cell Biol* 23: 345-356, 2013.
36. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC and Chen L: Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. *Proc Natl Acad Sci USA* 103: 10660-10665, 2006.
37. Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH and Landen CN: Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. *Oncotarget* 5: 7065-7080, 2014.
38. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM and White E: Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. *Cancer Cell* 7: 227-238, 2005.
39. Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R and Suntharalingam M: Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. *Lung cancer* 68: 84-88, 2010.
40. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, *et al*: Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: Phase II results from the North Central Cancer Treatment Group (N044B). *J Thorac Oncol* 3: 516-520, 2008.
41. Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN and Erlichman C: A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: A phase 2 consortium study. *Cancer* 116: 3463-3468, 2010.
42. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Vigano L, Maur M, Capri G, *et al*: Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. *Eur J Cancer* 44: 1829-1834, 2008.
43. Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, *et al*: Rationally designed treatment for solid tumors with MAPK pathway activation: A phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. *Mol Cancer Ther* 10: 1509-1519, 2011.
44. Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, *et al*: A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 66: 151-158, 2010.
45. Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, *et al*: A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. *J Thorac Oncol* 10: 172-180, 2015.
46. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, *et al*: A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. *Cancer Chemother Pharmacol* 59: 207-215, 2007.
47. Castedo M, Perfettini JL, Roumier T and Kroemer G: Cyclin-dependent kinase-1: Linking apoptosis to cell cycle and mitotic catastrophe. *Cell Death Differ* 9: 1287-1293, 2002.
48. Sakurikar N, Eichhorn JM and Chambers TC: Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. *J Biol Chem* 287: 39193-39204, 2012.
49. Hou Y, Allan LA and Clarke PR: Phosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell death. *J Cell Sci* 130: 502-511, 2017.
50. Harley ME, Allan LA, Sanderson HS and Clarke PR: Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. *The EMBO J* 29: 2407-2420, 2010.
51. Allan LA and Clarke PR: Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. *Mol Cell* 26: 301-310, 2007.
52. Clarke PR and Allan LA: Destruction's our delight: Controlling apoptosis during mitotic arrest. *Cell Cycle* 9: 4035-4036, 2010.
53. Lu Z and Hunter T: Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. *Cell Cycle* 9: 2342-2352, 2010.
54. Millman SE and Pagano M: MCL1 meets its end during mitotic arrest. *EMBO Rep* 12: 384-385, 2011.
55. Kreis NN, Louwen F and Yuan J: Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. *Oncogene* 34: 1758-1767, 2015.
56. Gavet O and Pines J: Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. *Dev Cell* 18: 533-543, 2010.
57. Rata S, Suarez Peredo Rodriguez MF, Joseph S, Peter N, Echegaray Iturra F, Yang F, Madzvamuse A, Ruppert JG, Samejima K, Platani M, *et al*: Two interlinked bistable switches govern mitotic control in mammalian cells. *Curr Biol* 28: 3824-3832 e3826, 2018.
58. Diril MK, Ratnacaram CK, Padmakumar VC, Du T, Wasser M, Coppola V, Tessarollo L and Kaldis P: Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. *Proc Natl Acad Sci USA* 109: 3826-3831, 2012.
59. Saito M, Mulati M, Talib SZ, Kaldis P, Takeda S, Okawa A and Inose H: The indispensable role of cyclin-dependent kinase 1 in skeletal development. *Sci Rep* 6: 20622, 2016.
60. Soni DV, Sramkoski RM, Lam M, Stefan T and Jacobberger JW: Cyclin B1 is rate limiting but not essential for mitotic entry and progression in mammalian somatic cells. *Cell Cycle* 7: 1285-1300, 2008.

